GLP1R and familial pancreatic carcinoma: A TriNetX study by Arunkumar et al. compared pancreatic cancer rates in individuals using GLP‐1 RAs versus those on metformin, reporting a 53% rate reduction (HR = 0.47; 95% CI, 0.42–0.52), which aligns with our results.46